Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: Role of oxidative stress and PRMT-1

Clinical Science

Volumn 118, Issue 9, 2010, Pages 583-592

  Savoia, Carmine ^a,b,c   Ebrahimian, Talin ^a   Lemarié, Catherine A ^a   Paradis, Pierre ^a   Iglarz, Marc ^a   Amiri, Farhad ^a   Javeshghani, Danesh ^a   Schiffrin, Ernesto L ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; Endothelium; Hyperhomocysteinaemia; Peroxisomeproliferator activated receptor (PPAR ); Rosiglitazone

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN ARGININE METHYLTRANSFERASE; ROSIGLITAZONE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL DIET; CONTROLLED STUDY; FEMALE; HETEROZYGOTE; HYPERHOMOCYSTEINEMIA; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; VASCULAR ENDOTHELIUM; VASODILATATION; WILD TYPE;

EID: 76849109173     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090289     Document Type: Article

References (51)

1. Touyz, R. and Schiffrin, E. L. (2006) Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vasc. Pharmacol. 45, 19-28
2. Tontonoz, P., Hu, E. and Spiegelman, B. M. (1994) Stimulation of adipogenesis in fibroblasts by PPARγ, a lipid-activated transcription factor. Cell 79, 1147-1156
3. Olefsky, J. M. and Saltiel, A. R. (2000) PPARγ and the treatment of insulin resistance. Trends Endocrinol. Metab. 11, 362-368
4. Duan, S. Z., Usher, M. G. and Mortensen, R. M. (2008) Peroxisome proliferators-activated receptor-γ-mediated effects in the vasculature. Circ. Res. 102, 283-294
5. Evans, R. M., Barish, G. D. and Wang, Y. X. (2004) PPARs and the complex journey to obesity. Nat. Med. 10, 355-361 6 Tontonoz, P., Nagy, L., Alvarez, J. G., Thomazy, V. A. and Evans, R. M. (1998) PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252
6. Marx, N., Sukhova, G. M., Murphy, C., Libby, P. and Plutzky, J. (1998) Macrophages in human atheroma contain PPARγ: differentiation-dependent PPARγ expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153, 17-23
7. Ricote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J., Witztum, J. L., Auwerx, J., Palinski, W. and Glass, C. K. (1998) Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U.S.A. 95, 7614-7619
8. Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Pineda-Torra, I., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J. C. et al. (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393, 790-793
9. Chinetti, G., Gbaguidi, G. F., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, J., Fruchart, J. C., Tedgui, A., Najib-Fruchart, J. and Staels, B. (2000) CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 10, 2411-2417
10. Robinson, J. G. (2008) Should we use PPAR agonists to reduce cardiovascular risk? PPAR Res, 28, 891425
11. Welch, G. N. and Loscalzo, J. (1998) Homocysteine and atherothrombosis. N. Engl. J. Med. 338, 1042-1050
12. Eikelboom, J.W., Lonn, E., Genest, J., Jr, Hankey, G. and Yusuf, S. (1999) Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med. 131, 363-375
13. Chen, Z., Karaplis, A. C., Ackerman, S. L., Pogribny, I. P., Melnyk, S., Lussier-Cacan, S., Chen, M. F., Pai, A., John, S.W., Smith, R. S. et al. (2001) Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet. 10, 433-443
14. Kang, S. S., Zhou, J., Wong, P. W., Kowalisyn, J. and Strokosch, G. (1998) Intermediate homocysteine: a thermolabile variant of methylenetetrahydrofolate reductase. Am. J. Hum. Genet. 43, 414-421
15. Frosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A., Matthews, R. G., Boers, G. J., van den Heijer, M., Kluijtmas, L. A. and van den Heuvel, L. P. (1995) A candidate genetic risk factor for vascular diseas: a common mutation in methylenetetrahydrofolate reductase. Nat. Gen. 10, 111-113
16. Neves, M. F., Endemann, D., Amiri, F., Virdis, A., Pu, Q., Rozen, R. and Schiffrin, E. L. (2004) Small artery mechanics in hyperhomocysteinemic mice: effects of angiotensin II. J. Hypertens. 22, 959-966
17. Javeshghani, D., Sairam, R. M., Schiffrin, E. L. and Touyz, R. M. (2007) Increased blood pressure, vascular inflammation, and endothelial dysfunction in androgen-deficient follitropin receptor knockout male mice. J. Am. Soc. Hyper. 1, 353-361
18. Rothe, G. and Valet, G. (1990) Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′-dichlorofluorescein. J. Leukocyte Biol. 47, 440-448
19. Miller, F. J. Jr., Gutterman, D. D., Rios, C. D., Heistad, D. D. and Davidson, B. L. (1998) Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ. Res. 82, 1298-1305
20. Savoia, C., Ebrahimian, T., He, Y., Gratton, J. P., Schiffrin, E. L. and Touyz, R. M. (2006) Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J. Hypertens. 24, 2417-2422
21. Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M. and Haussler, D. (2002) The human genome browser at UCSC, Genome. Res. 12(6), 996-1006
22. Reference deleted
23. Loots, G., Ovcharenko, I., Pachter, L., Dubchak, I. and Rubin, E. (2002) rVISTA for comparative sequence-based discovery of functional transcription factor binding sites. Genome. Res. 12, 832-839
24. Reference deleted
25. Savoia, C. and Schiffrin, E. L. (2006) Inhibition of the renin angiotensin system: implications for the endothelium. Curr. Diabetes Rep. 6, 274-278
26. Touyz, R. and Schiffrin, E. L. (2004) Reactive oxygen species in vascular biology: implications in hypertension. Histochem. Cell. Biol. 122, 339-352
27. Heikkinen, S., Auwerx, J. and Argmann, C. A. (2007) PPARγ in human and mouse physiology. Biochim. Biophys. Acta 1771, 999-1013
28. Schaalan, M., El-Abhar, S., Maged, B. and El-Deshary, E. S. (2009) Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride. J. Diabetes Complicat. 23, 199-208
29. Li, A. C., Brown, K. K., Silvestre, M. J., Wilson, T. M., Palinski, W. and Glass, C. K. (2000) Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL-receptor knock-out mice. J. Clin. Invest. 106, 523-531
30. Minamikawa, J., Tanaka, S., Yamauchi, M., Inoue, D. and Koshiyama, H. (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 83, 1818-1820
31. Chen, Z., Ishibashi, S., Perrey, S., Osuga, J., Gotoda, T., Kitamine, T., Tamura, Y, Okazaki, H., Yahagi, N., Iizuka, Y. et al. (2001) Troglitazone inhibits atherosclerosis in apolipoprotein E-20 knock-out mice: pleiotropic effect on CD36 expresion and HDL. Arterioscl. Thromb. Vasc. Biol. 21, 372-377
32. Marx, N., Schonbeck, U., Lazar, M. A., Libby, P. and Plutzky, J. (1998) Peroxisome proliferator activated receptor γ activators inhibit gene expression and migration in human vascular smooth cells. Circ. Res. 83, 1097-1103
33. Bruemmer, D., Yin, F., Liu, J., Berger, J. P., Sakai, T., Blaschke, F., Fleck, E., Van Herle, A. J., Forman, B. M. and Law, R. E. (2003) Regulation of the growth arrest and DNA damage inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor γ in vascular smooth muscle cells. Circ. Res. 93, e38-e47
34. Ross, R. (1999) Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340, 115-126
35. Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S., Wakino, S., Noh, G., Palinski, W., Hsueh, W. A. and Law, R. E. (2001) Troglitazone inhibits formation of early atherosclerotic lesion in diabetic and non diabetic low density lipoprotein receptor deficient mice. Arterioscl. Thromb. Vasc. Biol. 21, 365-371
36. Murthy, S. N., Obregon, D. F., Chattergoon, N. N., Fonseca, N. A., Mondal, D., Dunne, J. B., Diez, J. G., Jeter, Jr, J. R, Kadowitz, P. J., Agrawal, K.C., McNamara, D. B. and Fonseca, V. A. (2005) Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed high methionine diet. Metab. Clin. Expt. 54, 645-652
37. Lonn, E. M., Gerstein, H. C., Sheridan, P., Smith, S., Diaz, R., Mohan, V., Bosch, J., Yusuf, S. and Dagenais, G. R. (2009) Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J. Am. Coll. Cardiol. 53, 2028-2035
38. Varghese, A., Yee, M. S., Chan, C. F., Crowe, L. A., Keenan, N. G., Johnston, D. G. and Pennell, D. J. (2009) Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 11, 24-32
39. Schachinger, V., Britten, M. B. and Zehier, A. M. (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 101, 1899-1906
40. Bolayirli, I. M., Aslam, M., Balci, H., Altug, T., Hacibekiroglu, M. and Seven, A. (2007) Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci. 81, 121-127
41. Virdis, A., Iglarz, M., Neves, M. F., Amiri, F., Touyz, R. M., Rozen, R. and Schiffrin, E. L. (2003) Effect of hyperhomocysteinemia and hypertension on endothelial function in methylene tetrahydrofolate reductase-deficient mice. Arterioscl. Thromb. Vasc. Biol. 23, 1352-1357
42. Valance, P. and Leiper, J. (2004) Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohyddrolase pathway. Arterioscl. Thromb. Vasc. Biol. 24, 1023-1030 44 Lentz, S. R. and Rodinov, R. N., (2003) Dayal, S. Hyperhomocysteinemia, endothelial dysfunction and cardiovascular risk: the potential role of ADMA. Atherosclerosis 4, 61-65
43. Hayden, M. R. (2008) Homocysteine competes for the peroxisome proliferator-activated receptor nuclear receptors. J. Cardiometab. Syndr. 3, 70-71
44. Son, N. H., Park, T. S., Yamashita, H., Yokoyama, M., Huggins, L. A., Okajima, K., Homma, S., Szabolcs, M. J., Huang, L. S. and Goldberg, I. J. (2007) Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice. J. Clin. Invest. 117, 2791-2801
45. Böger, R. H., Sydow, K., Borlak, J., Thum, T., Lenzen, H., Schubert, B., Tsikas, D. and Bode-Böger, S. M. (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosyl methionine-dependent methyltransferases. Circ. Res. 87, 99-105
46. Thorp, E., Kuriakose, G., Shah, Y. M., Gonzalez, F. J. and Tabas, I. (2007) Pioglitazone increases macrophage apoptosis and claque necrosis in advanced atherosclerotic lesions of non diabetic low-density lipoprotein receptor-null mice. Circulation 116, 2182-2190
47. Tontonoz, P., Nagy, L., Alvarez, J. G., Thomazy, V. A. and Evans, R. M. (1998) PPAR γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252
48. Nissen, S. E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471
49. Psaty, B. M. and Furberg, C. D. (2007) Rosiglitazone and cardiovascular risk. N. Engl. J. Med. 356, 522-2524
50. Semple, R. K., Chatterjee, V. K. and O'Rahilly, S. (2006) PPAR γ and human metabolic disease. J. Clin. Invest. 116, 581-589
51. Luan, J., Brawne, P. O., Harding, A. H., Halsall, D. J., O'Rahilly, S., Chatterjee, V. K. and Wareham, N. J. (2001) Evidence of gene-nutrient interaction at the PPAR γ locus. Diabetes 50, 686-689